Intravenous carbamazepine: a new formulation of a familiar drug

References

• Vajda FJ, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disord. 2014;16(4):395–408.
   PubMed Web of Science ®Google Scholar
• WHO model list of essential medicines. 2015 [cited 2017 Jan 30]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
   Google Scholar
• Arzimanoglou A, Ben-Menachem E, Cramer J, et al. The evolution of antiepileptic drug development and regulation. Epileptic Disord. 2010;12(1):3–15.
   PubMed Web of Science ®Google Scholar
• Jost J, Preux PM, Druet-Cabanac M, et al. How to reduce the treatment gap for people with epilepsy in resource-limited settings by innovative galenic formulations: a review of the current situation, overview of potential techniques, interests and limits. Epilepsy Res. 2016;119:49–61.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402–408.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:522–530.
   PubMed Web of Science ®Google Scholar
• WHO Epilepsy Fact Sheet. 2017 [cited 2017 Mar 24]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1.
   Google Scholar
• Conway JM, White JR, Birnbaum AK, et al. Safety of an IV formulation of carbamazepine. Epilepsy Res. 2009;84(2–3):242–244.
   PubMed Web of Science ®Google Scholar
• Marino SE, Birnbaum AK, Leppik IE, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91(3):483–488.
   PubMed Web of Science ®Google Scholar
• Shorvon S. Handbook of epilepsy treatment. Oxford, UK: Wiley-Blackwell. 2011. p. 365–377.
   Google Scholar
• Patel SI, Birnbaum AK, Cloyd JC, et al. Intravenous and intramuscular formulations of antiseizure drugs in the treatment of epilepsy. CNS Drugs. 2015;29(12):1009–1022.
   PubMed Web of Science ®Google Scholar
• Trinka E, Kalviainen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017;44:65–73.
   PubMed Web of Science ®Google Scholar
• Established Status Epilepticus Treatment Trial (ESETT). (NCT01960075). [cited 2017 Mar 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT01960075?term=NCT01960075&rank=1.
   Google Scholar
• Alrashood ST. Carbamazepine. Profiles Drug Subst Excip Relat Methodol. 2016;41:133–321.
   PubMedGoogle Scholar
• Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol. 1984;25(2):228–234.
   PubMed Web of Science ®Google Scholar
• Majkowski J, Dlawichowska E, Sobieszek A. Carbamazepine effects on afterdischarge, memory retrieval, and conditioned avoidance response latency in hippocampally kindled cats. Epilepsia. 1994;35(1):209–215.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Crunelli V, Samanin R. Seizure susceptibility and anticonvulsant activity of carbamazepine, diphenylhydantoin and phenobarbital in rats with selective depletions of brain monoamines. Neuropharmacology. 1978;17(8):643–647.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Samanin R. Decreased anticonvulsant activity of carbamazepine in 6-hydroxydopamine-treated rats. Eur J Pharmacol. 1977;41(3):336–336.
   PubMed Web of Science ®Google Scholar
• Wada JA, Sato M, Wake A, et al. Prophylactic effects of phenytoin, phenobarbital, and carbamazepine examined in kindling cat preparations. Arch Neurol. 1976;33(6):426–434.
   PubMedGoogle Scholar
• Czuczwar SJ, Turski L, Kleinrok Z. Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid. Epilepsia. 1982;23(4):377–382.
   PubMed Web of Science ®Google Scholar
• Bourgeois BF, Wad N. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice. J Pharmacol Exp Ther. 1984;231(2):411–415.
   PubMed Web of Science ®Google Scholar
• Gilbert TH, Teskey GC. Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of acute carbamazepine. Exp Brain Res. 2001;140(4):479–485.
   PubMed Web of Science ®Google Scholar
• Geradin AP, Abadie FV, Campestrini JA, et al. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm. 1976;4(6):521–535.
   PubMedGoogle Scholar
• Bertilsson L, Hojer B, Tybring G, et al. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther. 1980;27(1):83–88.
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Ekbom K, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975;8(5):337–341.
   PubMed Web of Science ®Google Scholar
• Levy RH, Lockard JS, Green JR, et al. Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. J Pharm Sci. 1975;64(2):302–307.
   PubMed Web of Science ®Google Scholar
• Pitlick WH, Levy RH. Time-dependent kinetics I: exponential autoinduction of carbamazepine in monkeys. J Pharm Sci. 1977;66(5):647–649.
   PubMed Web of Science ®Google Scholar
• Bourgeois BF, Wad N. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. Ther Drug Monit. 1984;6(3):259–265.
   PubMed Web of Science ®Google Scholar
• Burianova I, Borecka K. Routine therapeutic monitoring of the active metabolite of carbamazepine: is it really necessary? Clin Biochem. 2015;48(13–14):866–869.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Mintzer S, Pack AM, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11–27.
   PubMed Web of Science ®Google Scholar
• Tegretol (carbamazepine) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013.
   Google Scholar
• Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf. 2006;29(2):95–118.
   PubMed Web of Science ®Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998;54(8):639–643.
   PubMed Web of Science ®Google Scholar
• Mula M. Anticonvulsants - antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab. 2008;9(8):730–737.
   PubMed Web of Science ®Google Scholar
• Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet. 1978;3(2):128–143.
   PubMed Web of Science ®Google Scholar
• Strack DK, Leckband SG, Meyer JM. Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine. J Psychiatr Pract. 2009;15(6):442–448.
   PubMed Web of Science ®Google Scholar
• Punyawudho B, Cloyd JC, Leppik IE, et al. Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. Clin Pharmacokinet. 2009;48(5):313–320.
   PubMed Web of Science ®Google Scholar
• Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291–3301.
   PubMed Web of Science ®Google Scholar
• Abel S, Allan R, Gandelman K, et al. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig. 2008;28(7):409–420.
   PubMed Web of Science ®Google Scholar
• Luke DR, Wood ND, Tomaszewski KE, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) in subjects on hemodialysis. Nephrol Dial Transplant. 2012;27(3):1207–1212.
   PubMed Web of Science ®Google Scholar
• Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3(1):70–76.
   PubMed Web of Science ®Google Scholar
• Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. 1992;327(11):765–771.
   PubMed Web of Science ®Google Scholar
• Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313(3):145–151.
   PubMed Web of Science ®Google Scholar
• Ramsay RE, Wilder BJ, Berger JR, et al. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology. 1983;33(7):904–910.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet (London, England). 1995;345(8948):476–479.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wroe SJ, Dean AD, et al. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. E&B. 2002;3(2):140–146.
   Google Scholar
• Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet (London, England). 1999;354(9172):13–19.
   PubMed Web of Science ®Google Scholar
• Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107(3):165–175.
   PubMed Web of Science ®Google Scholar
• Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia. 1998;39(9):952–959.
   PubMedGoogle Scholar
• Wheless JW, Neto W, Wang S. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004;19(2):135–141.
   PubMed Web of Science ®Google Scholar
• Tolbert D, Cloyd J, Biton V, et al. Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. Epilepsia. 2015;56(6):915–923.
   PubMed Web of Science ®Google Scholar
• Lee D, Kalu U, Halford JJ, et al. Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: pooled tolerability results from two open-label trials. Epilepsia. 2015;56(6):906–914.
   PubMed Web of Science ®Google Scholar
• Schoeman JF, Elyas AA, Brett EM, et al. Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol. 1984;26(6):756–764.
   PubMed Web of Science ®Google Scholar
• Clark AM, Kriel RL, Leppik IE, et al. Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia. 2013;54(6):1099–1105.
   PubMed Web of Science ®Google Scholar
• Clark AM, Kriel RL, Leppik IE, et al. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia. 2013;54(6):1106–1111.
   PubMed Web of Science ®Google Scholar